Trial Information

Summary: A Phase I Study of IPI-493 in Patients with Advanced Malignancies

The purpose of this study is to determine the safety and tolerability of IPI-493 when given orally to patients with advanced solid tumor malignancies. The study will assess the effects of this drug on patients and their cancers by assessing the patients' side effects and through pharmacokinetics. Pharmacokinetics (PKs) is a way to determine the amount of drug in the patient's blood and to see how the body processes, distributes, metabolizes and eliminates the drug. This is done by frequent blood draws during the first four weeks of treatment.

IPI-493 is an oral, targeted therapy that is a heat shock protein. The target is HSP 90 which acts as a chaperone for "client" proteins involved in cancer cell proliferation, growth and survival. It is believed that blocking this process can damage cancer cells' ability to reproduce. IPI-493 is not approved by the FDA and is investigational.

Patient Inclusion Criteria:

• ECOG 0-1
• Patients will undergo a slit lamp eye exam
• PatientExclusionCriteria = Prior treatment with another heat shock protein
• Active keratitis or keratoconjunctivitis
• If patient has received > 450 mg/m2 of anthracycline, must have LVEF of > 45%

Not all eligibility criteria are listed. Additional criteria must be met in order to be eligible.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.